SG Americas Securities LLC Has $698,000 Stock Holdings in Simulations Plus, Inc. (NASDAQ:SLP)

SG Americas Securities LLC reduced its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 3.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 25,011 shares of the technology company’s stock after selling 958 shares during the quarter. SG Americas Securities LLC owned approximately 0.12% of Simulations Plus worth $698,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of SLP. JPMorgan Chase & Co. grew its stake in shares of Simulations Plus by 106.0% in the third quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock worth $1,517,000 after purchasing an additional 24,371 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Simulations Plus by 2.6% during the 3rd quarter. Principal Financial Group Inc. now owns 87,273 shares of the technology company’s stock worth $2,794,000 after buying an additional 2,226 shares during the period. Franklin Resources Inc. grew its position in shares of Simulations Plus by 7.6% in the 3rd quarter. Franklin Resources Inc. now owns 10,797 shares of the technology company’s stock valued at $342,000 after buying an additional 766 shares during the last quarter. Barclays PLC increased its stake in shares of Simulations Plus by 390.6% in the third quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock valued at $911,000 after buying an additional 22,669 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Simulations Plus by 4.4% during the third quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock worth $14,367,000 after acquiring an additional 18,924 shares during the last quarter. Institutional investors own 78.08% of the company’s stock.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total transaction of $635,200.00. Following the completion of the sale, the director now owns 3,442,584 shares in the company, valued at $109,336,467.84. The trade was a 0.58 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 19.40% of the company’s stock.

Simulations Plus Stock Up 1.4 %

Shares of NASDAQ SLP opened at $34.27 on Friday. The firm has a market cap of $688.48 million, a PE ratio of 85.68 and a beta of 0.80. The company’s fifty day simple moving average is $30.31 and its 200 day simple moving average is $32.70. Simulations Plus, Inc. has a 12-month low of $24.00 and a 12-month high of $51.22.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. BTIG Research reduced their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, October 24th. StockNews.com lowered shares of Simulations Plus from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Stephens initiated coverage on shares of Simulations Plus in a research note on Friday, November 15th. They set an “overweight” rating and a $39.00 target price for the company. William Blair restated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. Finally, KeyCorp increased their price target on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Simulations Plus has an average rating of “Moderate Buy” and a consensus price target of $49.40.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.